Where Will Salesforce Stock Be in 5 Years?
Salesforce (NYSE: CRM) just turned in a quarter that, on…
Buy
80
HIMS Quote, Financials, Valuation and Earnings
Last price:
$56.59
Seasonality move
:
-4.52%
Day range:
$52.09 - $57.38
52-week range:
$13.47 - $72.98
Dividend yield:
0%
P/E ratio:
81.97x
P/S ratio:
7.64x
P/B ratio:
23.05x
Volume:
41.1M
Avg. volume:
48.5M
1-year change:
177.66%
Market cap:
$12.7B
Revenue:
$1.5B
EPS (TTM):
$0.69
Analysts' Opinion
-
Consensus RatingHims & Hers Health has received a consensus rating of Hold. The company's average rating is a Hold based on 4 Buy ratings, 6 Hold ratings, and 1 Sell rating.
-
Price Target DownsideAccording to analysts' consensus price target of $47.56, Hims & Hers Health has an estimated downside of -15.9% from its current price of $56.56.
-
Price Target UpsideAccording to analysts, the highest upside price target is $85.00 representing 50.28% upside increase from its current price of $56.56.
Fair Value
-
According to the consensus of 11 analysts, Hims & Hers Health has -15.9% downside to fair value with a price target of $47.56 per share.
HIMS vs. S&P 500
-
Over the past 5 trading days, Hims & Hers Health has overperformed the S&P 500 by 3.73% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Hims & Hers Health does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Hims & Hers Health has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Hims & Hers Health reported revenues of $586M.
Earnings Growth
-
Hims & Hers Health has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Hims & Hers Health reported earnings per share of $0.20.
Enterprise value:
12.3B
EV / Invested capital:
--
Price / LTM sales:
7.64x
EV / EBIT:
112.26x
EV / Revenue:
6.91x
PEG ratio (5yr expected):
--
EV / Free cash flow:
52.16x
Price / Operating cash flow:
57.65x
Enterprise value / EBITDA:
93.28x
Gross Profit (TTM):
$1.4B
Return On Assets:
26.26%
Net Income Margin (TTM):
9.21%
Return On Equity:
37.84%
Return On Invested Capital:
37.84%
Operating Margin:
9.88%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $616.4M | $959.4M | $1.8B | $278.2M | $586M | |
| Gross Profit | $487.4M | $790.6M | $1.4B | $229.1M | $430.7M | |
| Operating Income | -$63M | -$8.3M | $109.9M | $9.9M | $57.9M | |
| EBITDA | -$55.2M | $2.1M | $132.3M | $12.9M | $66.2M | |
| Diluted EPS | -$0.29 | -$0.01 | $0.69 | $0.05 | $0.20 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $340.2M | $231.9M | $225.5M | $261.7M | $447M | |
| Total Assets | $345.9M | $382M | $376.3M | $448.1M | $891.7M | |
| Current Liabilities | $19.7M | $48.5M | $56.3M | $93.3M | $280.4M | |
| Total Liabilities | $53.4M | $54.3M | $63.6M | $103.6M | $342.5M | |
| Total Equity | $292.5M | $327.7M | $312.7M | $344.5M | $549.3M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $2.4M | $89.8M | $334.3M | $25.8M | $109.1M | |
| Cash From Investing | $12.1M | $5M | -$64.9M | $13M | -$32.8M | |
| Cash From Financing | -$14M | -$38.4M | -$100.6M | -$30.3M | -$23M | |
| Free Cash Flow | -$6.1M | $51.9M | $236.5M | $11.9M | $50.1M | |
HIMS
Sector
Market Cap
$12.7B
$33.4M
Price % of 52-Week High
77.5%
45.25%
Dividend Yield
0%
0%
Shareholder Yield
0.83%
-0.66%
1-Year Price Total Return
177.66%
-40%
Beta (5-Year)
1.846
0.653
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$55.40
200-day SMA
Buy
Level
$30.12
Bollinger Bands (100)
Buy
Level
26.79 - 50.67
Chaikin Money Flow
Buy
Level
383.9M
20-day SMA
Buy
Level
$54.85
Relative Strength Index (RSI14)
Buy
Level
59.93
ADX Line
Buy
Level
28.82
Williams %R
Neutral
Level
-63.5126
50-day SMA
Buy
Level
$39.91
MACD (12, 26)
Buy
Level
4.51
25-day Aroon Oscillator
Buy
Level
52
On Balance Volume
Neutral
Level
551.8M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (16.0727)
Buy
CA Score
(Annual)
Level (2.0165)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (10)
Buy
Ohlson Score
Level (-2.3964)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (7)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Hims & Hers Health Inc is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, enabling them to access high-quality medical care for numerous conditions related to mental health, sexual health, dermatology, haircare and more.
Stock Forecast FAQ
In the current month, HIMS has received 4 Buy ratings 6 Hold ratings, and 1 Sell ratings. The HIMS average analyst price target in the past 3 months is $47.56.
-
Where Will Hims & Hers Health Stock Be In 1 Year?
According to analysts, the consensus estimate is that Hims & Hers Health share price will drop to $47.56 per share over the next 12 months.
-
What Do Analysts Say About Hims & Hers Health?
Analysts are divided on their view about Hims & Hers Health share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Hims & Hers Health is a Sell and believe this share price will rise from its current level to $25.00.
-
What Is Hims & Hers Health's Price Target?
The price target for Hims & Hers Health over the next 1-year time period is forecast to be $47.56 according to 11 Wall Street analysts, 4 of them rate the stock a Buy, 1 rates the stock a Sell, and 6 analysts rate the stock a Hold.
-
Is HIMS A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Hims & Hers Health is a Hold. 6 of 11 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of HIMS?
You can purchase shares of Hims & Hers Health via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Hims & Hers Health shares.
-
What Is The Hims & Hers Health Share Price Today?
Hims & Hers Health was last trading at $56.59 per share. This represents the most recent stock quote for Hims & Hers Health. Yesterday, Hims & Hers Health closed at $56.56 per share.
-
How To Buy Hims & Hers Health Stock Online?
In order to purchase Hims & Hers Health stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
2 Ultra Safe Dividend Stocks to Buy Now
Historically, blue-chip dividend stocks have been good choices for periods…
Where Will Asana Stock Be in 5 Years?
Asana stock hasn’t given many investors on Wall Street any…
Stock Ideas
Buy
67
Is MSFT Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 39x
Buy
65
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 46x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Alerts
Sell
31
REGN alert for May 31
Regeneron Pharmaceuticals [REGN] is down 19.04% over the past day.
Buy
55
RGC alert for May 31
Regencell Bioscience Holdings [RGC] is up 16.13% over the past day.
Sell
42
AMBA alert for May 31
Ambarella [AMBA] is down 15.13% over the past day.
